On September 2, 2021 The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), reported that they have discovered the mechanism using Canady Helios Cold Plasma (CHCP) to induce cell death in breast cancer (Press release, JCRI-ABTS, SEP 2, 2021, View Source [SID1234587202]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recently accepted for publication in the International Journal of Molecular Sciences, the article "Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA" described how research scientists at JCRI/ABTS treated four (4) breast cancer cell lines with Canady Helios Cold Plasma (CHCP) at different dosages and monitored the progress of apoptosis (cell death).

Jerome Canady, MD (CEO of USMI), stated "As we have proven, CHCP is a very promising adjuvant therapy to selectively combat many cancers, but our focus in this report is our work on breast cancer which affects over 3.5 million women in the US alone. Inhibition of cell proliferation, induction of apoptosis, and disruption of cell cycle were all observed during the early S-phase of the cell cycle. This news is auspicious because it shows CHCP treatment can be personalized for specific breast cancer types."

Canady Helios Cold Plasma or CHCP is a highly selective, non-thermal process developed by USMI for treating solid cancerous tumors during the surgical procedure. CHCP triggers both chemical and molecular changes in the cancer cells that cause significant stress and drastically decreases the cancer cell’s viability, leading to apoptosis. CHCP is proven to be safe and causes no thermal injury to normal tissue.

JCRI-ABTS and USMI have recently completed the first FDA-approved Phase I Clinical Trial to evaluate Cold Atmospheric Plasma for the treatment of cancer (IDE #190165). The clinical sites were Rush University Medical Center (Chicago, IL) and Sheba Medical Center (Ramat Gan, Israel)).

More information will be shared when Dr Canady presents at the annual Baird Global Healthcare Conference on September 14th at 10:15 AM ET.

On September 2, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") reported that a study recently published in BMC Cancer shows that blood tests, such as Epi proColon(R), can significantly increase the CRC screening rates in medically underserved populations (MUP) unwilling or unable to complete FIT or colonoscopy. For eligible participants, the rate of testing increased from 12.6% completing a FIT test the previous year to 93.5% with the blood test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Greg Hamilton, CEO of Epigenomics AG, commented: "CRC still is the second leading cause of cancer mortality in the U.S., despite the ability to reduce it through screening. Adherence to regular screening is key to earlier CRC detection thus reducing incidence and mortality. The findings now being published are in line with a series of previously published results that blood tests can make an important contribution to reducing the number of CRC related deaths, especially in medically underserved populations which are the most vulnerable."

In the U.S., many people are not up-to-date with CRC screening despite the available testing, with overall screening rates under 70%. This applies in particular to MUP, who share characteristics such as low income, lack of insurance or being underinsured. Although FIT has desirable characteristics for MUP, return rates are consistently low, around 10% in MUP compared to the general population. This was confirmed in the study now published. In the study, the patients were consecutively offered CRC screening by colonoscopy and FIT, according to the current guidelines for CRC screening. Only when both options were rejected, the blood test was offered. Of the 460 participants ultimately offered screening, no participant accepted the offer of colonoscopy, 30 (6.5%) chose FIT screening and 430 (93.5%) elected for mSEPT9 testing. Only two of the 30 participants who chose FIT returned the test (6.7%).

Hence, the study results show that the introduction of blood-based testing for CRC screening, when compared to FIT, has proven to be well-received by the participants, likely because of convenience and ease of testing. The result is another important contribution to the realization that FDA approved CRC screening blood tests should be incorporated into the screening paradigm, as this is a tangible solution to reduce CRC mortality.

On September 2, 2021 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the following investor conferences in September (Press release, CohBar, SEP 2, 2021, View Source [SID1234587237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Annual Global Investment Conference
September 13 – 15, 2021
Webcast: The presentation may be accessed via webcast on demand using the following link: View Source

Cantor Fitzgerald Virtual Global Healthcare Conference
Thursday, September 30, 2021 at 2:00pm ET
Webcast: The presentation may be accessed via webcast at the scheduled time, or following the presentation, using the following link: View Source

A replay of the webcasts will be available in the events section of the CohBar website for two weeks following the presentation.

On September 2, 2021 Alkermes plc (Nasdaq: ALKS) reported that management will participate in a fireside chat at the Citi 16th Annual BioPharma Virtual Conference on Thursday, Sept. 9, 2021 at 8:50 a.m. ET (1:50 p.m. BST) (Press release, Alkermes, SEP 2, 2021, View Source [SID1234587168]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 2, 2021 Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, reported that Christopher D. Roberts, Ph.D., has been appointed as Chief Executive Officer (Press release, Civetta Therapeutics, SEP 2, 2021, View Source [SID1234587203]). Dr. Roberts, who most recently served as Chief Scientific Officer of Black Diamond Therapeutics, brings more than 20 years of leadership experience discovering and developing novel therapies for oncology, immunology, virology and other indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Civetta has developed a unique discovery platform designed to rigorously investigate, validate and drug beta-propeller proteins. Because propeller domains are ubiquitous and play critical functions in pathways that are known contributors to pathogenesis, they provide broad opportunity as therapeutic targets," said Dr. Roberts. "I’m impressed by the work the team has done advancing its lead programs and platform. I look forward to joining the Civetta team in the discovery and development of novel, first-in-class therapies that can help patients across a variety of disease areas, from cancer, inflammation and immunology to neurodegeneration and metabolic disease."

Cameron Wheeler, Ph.D., who was serving as Chief Executive Officer at Civetta and is a Partner in the Biotherapeutics Group at Deerfield Management Company, will continue to serve as chairman of Civetta’s board of directors.

"The team at Civetta has done great work taking the early insights into beta-propeller science made by our founders at the Broad Institute and the Dana-Farber Cancer Institute and advancing them, to better understand their role in a variety of diseases," said Dr. Wheeler. "We see broad potential for targeting beta-propeller proteins and we’re working to identify novel, near-term therapeutics and establish the leading beta-propeller targeting platform in the industry. Attracting top talent like Chris will continue to be critical as we accelerate and expand our programs and pipeline."

Prior to joining Black Diamond, Chris served as an Entrepreneur in Residence at SR One, the corporate venture capital arm of GlaxoSmithKline (GSK). Prior to SR One, Chris was the Vice President (VP) of Chemistry and Early Development at Syros Pharmaceuticals, Inc., a publicly traded biotechnology company focused on gene control and drugging transcription, where he built and led a variety of discovery and development functions and helped guide two oncology assets into clinical development. Prior to joining Syros, Chris held numerous positions of increasing responsibility at GSK, including VP and Head of the Host Defense Discovery Performance Unit, and also led multiple clinical development projects. He joined GSK as Senior Director of Hepatitis C Virus (HCV) Medicinal Chemistry via its acquisition of Genelabs Technologies. As a medicinal chemist at Genelabs, Chris was significantly involved in establishing Genelabs’ HCV research focus. His work has been extensively published.

Chris earned a Ph.D. in Organic Chemistry from the University of California, Riverside, and completed a post-doctoral fellowship at the University of Bern, Switzerland. He graduated with a B.A. in Chemistry from Whitworth University.